SML0216
布林佐胺
≥98% (HPLC)
别名:
（R）-4-（乙基氨基）-3,4-二氢-2-（3-甲氧基丙基）-2H-噻吩并[3,2-e] -1,2-噻嗪-6-磺酰胺1,1-二氧化物, AL 4862, （5R）-5-乙基氨基-3-（3-甲氧基丙基）-2,2-二氧代-2?6,9-二硫杂-3-氮杂双环[4.3.0]壬-7,10-二烯-8-磺酰胺
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H21N3O5S3
化学文摘社编号:
分子量:
383.51
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
布林佐胺, ≥98% (HPLC)
InChI
1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
SMILES string
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI key
HCRKCZRJWPKOAR-JTQLQIEISA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: ≥10 mg/mL
storage temp.
−20°C
Quality Level
Gene Information
human ... CA2(760)
正在寻找类似产品? 访问 产品对比指南
相关类别
Application
在黑色素结合测定中，布林佐胺已被用作黑色素结合化合物或药物。它也被用作碳酸酐酶抑制剂（CAI）。
Biochem/physiol Actions
布林佐胺是一种用于降低眼压的碳酸酐酶 II 抑制剂。
布林佐胺是碳酸酐酶 II 抑制剂
General description
布林佐胺是一种小分子量的化合物，能结合黑色素。该药可用于眼部治疗。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
John H K Liu et al.
Ophthalmology, 118(10), 1995-2000 (2011-06-17)
A core assumption for the 1-eye therapeutic trial of ocular hypotensive medications is the symmetrical reduction of intraocular pressure (IOP) in paired eyes. This assumption was evaluated for 24-hour IOP reduction in patients who underwent monotherapy or adjunctive therapy. Database
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality
Ivan Goldberg et al.
Journal of glaucoma, 21(1), 55-59 (2010-11-05)
To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(5), 685-690 (2011-03-10)
To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. 6-month, multicenter, open-label, prospective, switch study
To Be or Not to Be Protonated: Atomic Details of Human Carbonic Anhydrase-Clinical Drug Complexes by Neutron Crystallography and Simulation.
Kovalevsky A, et al.
Structure, 26(3), 383-390 (2018)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持